ImmunoPrecise Antibodies Ltd. - Common Stock (IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQIPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced mRNA-based antigen expression expertise with IPA’s in silico and wet-lab antibody discovery capabilities.

ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors.

ImmunoPrecise Antibodies Ltd. (NASDAQIPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share.

ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQIPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million “at-the-market” equity offering program (the “ATM Program”) alongside the full conversion of its outstanding debenture with Yorkville Advisors, significantly enhancing the Company’s capital structure.

In a world where healthcare innovation is accelerating, companies leveraging artificial intelligence are leading the charge in transforming patient care, diagnostics, and therapeutic solutions. Their advancements in smart disinfection, AI-designed therapies, precision gene editing, and cardiovascular diagnostics are not only reshaping their industries but also unlocking tremendous growth potential. Here's how these cutting-edge companies are redefining the future of healthcare.

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQIPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai™ platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. Enhancements are aimed at increased patentability, extended stability and resistance to degradation, improved administration routes for greater compliance, reduced dosing requirements, and more efficient manufacturing methods. The Company’s GLP-1-like alternatives are currently being evaluated for potential transdermal delivery as non-invasive alternatives to injections. These novel constructs represent the Company's first fully AI-generated assets, complementing their growing portfolio of AI-assisted and laboratory-developed therapies.

ImmunoPrecise Antibodies Ltd. (NASDAQIPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency.

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQIPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company’s strategic direction and long-term potential through substantial share purchases.

VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter (“Q2”) of its 2025 fiscal year (“FY25”), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period.

The latest breakthroughs from leading innovators across healthcare, technology, and energy sectors spotlight with each of the companies below pushing boundaries in their fields. From pioneering antibody therapies for cancer and expanding biotech treatment options to advancing electric vehicle production, adopting blockchain-focused strategies, and driving demand in mmWave wireless technology, these companies are reshaping the landscape of their industries.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by 2028. The TATX-112 program, dedicated to the development of specialized antibodies for cancer treatment, has shown encouraging results, successfully targeting cells that express a protein known as TrkB. This achievement has paved the way for several promising candidates for further development.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments.

ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQIPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently peer-reviewed and published in the prestigious journal Autophagy. Titled "Development and Characterization of Phospho-Ubiquitin Antibodies to Monitor PINK1-PRKN Signaling in Cells and Tissue," this study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA’s research initiatives. These achievements validate the methodologies that underpin IPA’s proprietary Foundation AI model, LENSai, which leverages similar computational and AI approaches to innovate drug discovery.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. (Biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, jointly announce that the two parties have entered into a Material Transfer and Evaluation Agreement (MTEA) pertaining to a Talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. Under this MTEA, Biotheus will obtain the rights to further evaluate the suitability of Talem’s Artificial Intelligence (AI)-enhanced TATX-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) NASDAQ: IPANASDAQIPA)

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQIPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year (“FY25”), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQIPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQIPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's management team invites shareholders and all interested parties to attend. Admission to the Global Investment Conference is free to qualified investors.